Nippon Shinyaku Sets Up Promotion Agreement With Pfizer For Tramal In Japan
This article was originally published in PharmAsia News
Executive Summary
Nippon Shinyaku and Pfizer signed a license agreement allowing Pfizer to begin Japan promotion of the cancer and chronic pain drug Tramal (tramadol) sold by Nippon Shinyaku and the tramadol sustained formulation NS-24, which has been in Phase III trials since April 2012.
Nippon Shinyaku and Pfizer signed a license agreement Sept. 30 allowing Pfizer to begin Japan promotion of the cancer and chronic pain drug Tramal (tramadol) sold by Nippon Shinyaku and the tramadol oral sustained formulation NS-24, which has been in Phase III trials since April 2012. Pfizer will begin sole promotion of Tramal Dec. 1, but Nippon Shinyaku will continue to carry out sales. Nippon Shinyaku launched the drug in September 2010 for use in treatment where non-analgesics are not efficient, but since the approval of the drug for chronic pain treatment in June 2013, the scope of the drug has spread to the orthopedic and general medicine areas. Nippon Shinyaku felt that entrusting Pfizer with promotional activities would be the best way to maximize Tramal’s value. (Click Here For More – Japanese Language
)
“Nippon Shinyaku Agrees With Pfizer To Promote Tramal Capsules For Chronic Pain From December” - mixonline.jp 10/1/2013